文献速递肺栓塞与肺血管病呼吸危重症与机械通气

成人肺移植术后静脉血栓栓塞症的单中心经验

[A single-center experience of venous thromboembolism after adult lung transplantation].
PubMed 文献 · Zhonghua Jie He He Hu Xi Za Zhi · 2019-01-01

回顾性分析124例肺移植受者,术后VTE发生率为25.8%,中位发生时间22.5天,DVT占93.8%;VTE组ECMO使用率90.6%显著高于非VTE组的69.6%(P=0.033)。抗凝治疗后3个月血管完全再通率65.6%。

要点

  • 肺移植术后VTE发生率为25.8%,以DVT为主。
  • ECMO使用与术后VTE风险升高相关(90.6% vs 69.6%,P=0.033)。
  • 建议肺移植围术期常规筛查VTE并及时抗凝。

核心结论

  • VTE是肺移植术后常见并发症,ECMO应用可能是主要高危因素。
  • 建议肺移植受者常规进行VTE筛查并及时启动抗凝治疗。

研究设计与样本

  • 回顾性单中心研究,纳入2017年3月至2018年9月接受肺移植的124例终末期肺疾病患者。
  • 单肺移植78例(62.9%),双肺移植46例(37.1%)。
  • DVT通过血管超声诊断,肺栓塞通过CT肺动脉造影或通气/灌注扫描诊断。

主要发现

  • 术后32例发生VTE,总发生率为25.8%,中位发生时间22.5天(范围4-295天)。
  • VTE中DVT占93.8%(30/32),累及1-8根静脉(平均2.83±1.86根),下肢DVT占60.0%,上肢DVT占56.7%(P>0.05)。
  • 肺栓塞4例(12.5%),其中2例仅表现为肺栓塞不伴DVT。
  • VTE组ECMO使用率90.6%(29/32),显著高于非VTE组的69.6%(64/92,P=0.033)。
  • PICC置入率在VTE组96.9%(31/32)与非VTE组81.5%(75/92)间差异无统计学意义(P=0.067)。

关键数值与推荐

  • 术前预防性抗凝52例(41.9%),术后预防性抗凝69例(55.6%)。
  • 30例(93.7%)采用低分子肝素充分抗凝,2例(6.3%)采用低分子肝素序贯华法林抗凝。
  • 抗凝治疗后3个月血管完全再通率65.6%(21/32),部分再通率34.4%(11/32)。
  • 3例发生抗凝相关出血并发症,均未导致严重后果。

临床怎么用

  • 肺移植围术期应常规筛查VTE,尤其对使用ECMO的患者。
  • 发现VTE后应及时启动抗凝治疗,低分子肝素为基础方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To investigate the incidence of venous thromboembolism (VTE) in lung transplant (LT) recipients. Methods: The clinical data on 124 consecutive patients who underwent lung transplant at Lung Transplantation Center of China-Japan Friendship Hospital from March 2017 to September 2018 were retrospectively collected. Deep venous thrombosis (DVT) was ascertained by vascular ultrasound. Pulmonary embolism (PE) was diagnosed by either chest computed tomography pulmonary angiogram or ventilation/perfusion scan. The risk factors in those patients with postoperative VTE were studied. Results: A total of 124 lung transplant recipients including 78 single lung transplant recipients (62.9%) and 46 bilateral lung transplant recipients(37.1%) were enrolled. Preoperative and postoperative prophylactic anticoagulant was used in 52 patients(52/124, 41.9%) and 69 patients(69/124, 55.6%) respectively. Thirty-two patients developed postoperative VTE among 124 consecutive patients. The overall incidence rate of VTE among 124 LT recipients was 25.8%. The median time to VTE episode following lung transplant was 22.5 days (range 4-295 days). The percentage of DVT in VTE was 93.8%(30/32), involving 1-8 (2.83±1.86) veins. And 60.0% of DVT was from lower extremities and 56.7% located in upper extremities (P>0.05). Four patients (4/32,12.5%) had PE episodes, and half of them suffered from only PE without DVT. The use of extracorporeal membrane oxygenation (ECMO) in 32 patients with VTE was 90.6% (29/32), which was significantly higher than that without VTE (64/92,69.6%, P=0.033). However, there was no difference in the use of peripherally inserted central catheter (PICC) between two groups (96.9% vs 81.5%, P=0.067). Resolution of VTE was successfully accomplished by anticoagulant therapy with long-term use of low molecular weight heparin in 30 patients (93.7%) and followed by oral warfarin in 2 patients (6.3%). Three months follow-up data after anticoagulant therapy showed that total and partial vascular recanalization rate was 65.6%(21/32) and 34.4%(11/32), respectively. Despite anticoagulation-related bleeding complications in three patients, no serious consequences occurred. Conclusions: VTE was frequent in LT recipients. It was speculated that ECMO utilization may be a major risk factor for high incidence of VTE in LT recipients. Aggressive VTE screening/treatment protocols were suggested to be implemented in LT recipients. 目的: 探讨肺移植术后静脉血栓栓塞症(VTE)的发生情况。 方法: 回顾性分析2017年3月1日至2018年9月30日在中日友好医院接受肺移植的124例终末期肺疾病患者的临床资料,统计其肺移植术后深静脉血栓形成(DVT)和肺栓塞的发生时间、可能的高危因素及治疗转归等情况。 结果: 共124例肺移植受者,其中单肺移植78例(62.9%),双肺移植46例(37.1%);术前给予预防性抗凝52例(41.9%),术后预防性抗凝69例(55.6%);术后共32例患者发生VTE(25.8%),中位发生时间为术后22.5 d(4~295 d),其中30例(93.8%)发生DVT,病变累及1~8根静脉血管[平均(2.8±1.9)根],下肢DVT占60.0%,上肢DVT占56.7%(P>0.05)。4例(4/32,12.5%)发生肺栓塞,其中2例为同时合并DVT和肺栓塞。32例肺移植术后发生VTE的受者中,体外膜式氧合(ECMO)的使用率为90.6%(29/32),明显高于未发生VTE的肺移植受者(64/92,69.6%,P=0.033)。经外周置入中心静脉导管(PICC)的置入率在发生VTE(31/32,96.9%)与未发生VTE(75/92,81.5%)的两组患者间差异无统计学意义(P=0.067)。30例(30/32,93.7%)患者采用低分子肝素充分抗凝,2例(2/32,6.3%)采用低分子肝素序贯华法林抗凝,均随访至充分抗凝治疗后3个月,血管完全再通率为65.6%(21/32),部分再通率为34.4%(11/32)。3例发生抗凝相关出血并发症,均未导致严重后果。 结论: VTE是肺移植术后常见并发症,ECMO应用为主要高危因素。VTE筛查应常规纳入肺移植围术期患者管理中,及时发现VTE并启动抗凝治疗。.

来源:Zhonghua Jie He He Hu Xi Za Zhi,查看原文。版权归原作者所有。

引用

  1. Zhao L, Wang C, Chen JY, et al. [A single-center experience of venous thromboembolism after adult lung transplantation]. Zhonghua Jie He He Hu Xi Za Zhi. 2019. PMID: 31484244. doi:10.3760/cma.j.issn.1001-0939.2019.09.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。